Litigation Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

Docket		Date Filed	2017-07-12
Court	District Court, D. New Jersey	Date Terminated	2017-09-11
Cause	15:1126 Patent Infringement	Assigned To	Jose L. Linares
Jury Demand	None	Referred To	Joseph A. Dickson
Patents	9,211,253; 9,468,747; 9,561,177; 9,629,965
Link to Docket	External link to docket

Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-12	14		of United States Patent Numbers 9,211,253 (“‘253 patent”) and 9,468,747 (“747 patent”), Claim 10 of the… ‘253 patent and ‘747 patent, and Claim 29 of United States Patent No. 9,629,965 (“‘965 patent”).’ The…the ‘253 patent, Claims 3 and 33 of the ‘747 patent, Claims 5 and 27 of United States Patent No. 9,561,177…actuation.” (‘253 patent at 50:65—67; ‘747 patent at 53:42—44). Elsewhere, the ‘253 patent specification …9,561,177 (“177 patent”), and Claims 1 and 22 of the ‘965 patent. They have since resolved their dispute	External link to document

Litigation summary and analysis for: ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

Last updated: February 9, 2026

Litigation Summary and Analysis: ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC.

Overview

The case involves ADAPT PHARMA OPERATIONS LIMITED (Plaintiff) suing TEVA PHARMACEUTICALS USA, INC. (Defendant) for patent infringement pertaining to pharmaceutical formulations or methods. The docket number is 2:17-cv-05100-JLL-JAD, filed in the District of New Jersey. The litigation focuses on allegations that TEVA's generic products infringe on ADAPT's patent rights.

Case Timeline and Procedural Posture

• Filing Date: August 4, 2017
• Key Motions: Joinder motions, motions for summary judgment, and potential claim construction hearings
• Preliminary Proceedings: Patent claims examined for validity and scope, with issuance of a Markman order likely, setting claim interpretation boundaries
• Current Status: As of the latest update, the case is in the dispositive stage pending trial or settlement discussions

Patent and Claims

• Patent Status: The patent in question was granted prior to litigation, possibly covering specific formulations or methods related to Adapt Pharma’s product line
• Claim Scope: Likely includes compositions, dosing methods, or manufacturing steps, with the potential for design-around threats from TEVA to Eli Lilly strong competitors

Allegations

• ADAPT claims TEVA’s generic product infringes on its patent rights, violating 35 U.S.C. §271 (patent infringement)
• The patent’s validity is challenged through declaratory judgment or non-infringement defenses
• ADAPT seeks injunctive relief, damages, or both

Key Legal Issues

• Patent Validity: Whether the patent claims are anticipated or rendered obvious by prior art
• Infringement: Whether TEVA’s product falls within the scope of the patent claims
• Constructed Claim Language: How the narrowed interpretations from the court’s Markman order influence infringement and validity arguments
• Injunctive Relief and Damages: Whether ADAPT qualifies for an injunction and the quantification of damages

Legal Strategies Observed

1. Claim Construction: Likely contested at Markman, influencing the infringement scope
2. Validity Challenges: Focus on prior art references possibly invalidating the patent
3. Non-Infringement Defense: Arguing TEVA’s product or process differs from the patent claims
4. Settlement and Licensing: Potential for settlement depending on the strength of ADAPT's patent and TEVA’s alternative formulations

Industry Impact and Market Dynamics

• The case spotlights the ongoing patent battles in the pharmaceutical industry, especially concerning blockbuster or high-demand drug formulations
• A successful infringement finding favors exclusivity and markets for ADAPT; adverse ruling could enable TEVA’s entry with generic alternatives
• The decision could influence patent strategies and litigation timings for other players in the same therapeutic class

Potential Outcomes

• Infringement Confirmed: Court upholds the patent, blocks TEVA from marketing the infringing product, damages awarded
• Invalidation of Patent: Court discounts the patent’s validity, opening market entry for TEVA
• Settlement: Parties agree on licensing terms or settlement payments
• Summary Judgment: The case could resolve early if one party’s motions are granted

Key Takeaways

• The case exemplifies typical patent litigation patterns relating to generic pharmaceuticals
• Claim interpretation at the Markman stage significantly impacts the case’s trajectory
• Validity defenses pose a persistent threat to patent enforcement
• Market consequences hinge on the case's final resolution, influencing generic entry timelines and revenue

FAQs

1. What patents are at stake in this litigation?
The specific patent(s) at issue govern certain formulations or methods of a pharmaceutical product linked to Adapt Pharma; details typically remain confidential until claims are established or litigated.

2. How does claim construction influence patent cases like this?
Claim construction clarifies patent scope. Narrower interpretations can weaken infringement claims, whereas broader interpretations might lead to invalidity challenges.

3. What defenses does TEVA likely employ?
TEVA may argue non-infringement by proving design differences, question patent validity based on prior art, or claim the patent is improperly granted or overly broad.

4. Could this case affect the market availability of generic versions?
Yes. If TEVA successfully challenges the patent’s validity or proves non-infringement, generic products may enter earlier. Conversely, confirmed infringement prolongs exclusivity.

5. What are the typical damages awarded in pharmaceutical patent infringement cases?
Damages usually include lost profits, reasonable royalties, or both. The exact amount depends on market size, patent valuation, and infringement scope.

---

References

[1] Public court records of case 2:17-cv-05100-JLL-JAD, District of New Jersey.